| 14 April 2024, Sunday |

Russian Health Ministry Greenlights Joint Trials of AstraZeneca, Sputnik Light Vaccines

The Russian Health Ministry approved joint trials of coronavirus vaccines AstraZeneca and Sputnik Light, according to its registry of clinical trials approvals.

“Simple, blinded, randomized, phase I/II study to determine the safety and immunogenicity of a combination of AZD1222 and rAd26-S, administered in a heterologous prime-boost scheme, to prevent the novel coronavirus infection COVID-19 in adults,” the registry says.

The study will involve 150 patients and is scheduled to be completed on 2 March 2022.

Sputnik Light is a one-component version of the Russian coronavirus vaccine, Sputnik V, developed by the Russian Direct Investment Fund (RDIF) and Gamaleya Institute. According to RDIF, Sputnik Light has shown 79.4% efficacy in preventing COVID-19, higher than some other two-dose vaccines.

AstraZeneca is a UK-Swedish vaccine, developed by Oxford University and AstraZeneca. According to the data published in Lancet, the vaccine is 76.0% at preventing symptomatic COVID-19 following the first dose and 81.3% after the second dose.

  • Sputnik